

#3  
Sheet 1 of 1  
11/13/02

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31831C1	SERIAL NO. Not Yet Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT S.A. Smith	
		FILING DATE Herewith	GROUP

1033 U.S. PTO  
 09/928326  
 08/13/01

### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<i>R</i>	AA	WO 97/10819	03/1997	PCT			
<i>R</i>	AB	WO 95/07694	03/1995	PCT			
<i>R</i>	AC	WO 97/05875	02/1997	PCT			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>R</i>	AD	Connor, et al., " Antidaibet Efficacy of BRL 49653, a Potent Orally Active Insulin Sensitizing Agent, Assesses in the C57BL/KsJ <i>db/db</i> Diabetic Mouse by Non-invasive <sup>1</sup> H NMR Studies of Urine", (1997), <b>J. Pharm. Pharmacol.</b> , <b>49:3</b> , pp. 336-344. (XP002080751)
	AE	Lefebvre, et al., "Improving the action of insulin", <b>Clin. Invest. Med.</b> , <b>18:4</b> , pp. 340-347, (XP002080750) <b>DATE NEEDED</b>
<i>R</i>	AF	Skyler, J.S., "Insulin Therapy in Type II Diabetes", (1997), <b>Postgraduate Medicine</b> , <b>101:2</b> , pp. 85-96 (XP002080749)
<i>R</i>	AH	Nenrolles, et al., "New Therapeutic Agents of Non Insulin Dependent Diabetes", (1998), <b>Ann. D'Endocrinologie</b> , <b>59:2</b> , pp. 67-77 (XP002080748) English Translation included

EXAMINER 	DATE CONSIDERED 11/13/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	